Amicus and Perceptive call off SPAC merger for gene therapy spinout after recent setback
Roughly a month after Amicus Therapeutics reported an unexpected setback in a gene therapy planned to be spun out in a SPAC deal, the biotech and its blank check partner have called off the merger — the second high-profile SPAC decoupling in recent months.
Amicus will not spin out its gene therapy unit with Arya Sciences Acquisition IV, the fourth SPAC belonging to Joseph Edelman’s Perceptive, after all. The two say they have mutually agreed to end merger discussions, leaving Edelman with about another year to find a partner to take public.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.